An observational study in Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 17th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in Switzerland
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals
Ages 5–17
By country, each count listing its studies:
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2025.
This study's enrollment of 3,714 is above the median of 122 across 99 observational studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 39 across the 12 interventional studies, 150 across the 3 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Purpura, Thrombocytopenic, Idiopathic by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to describe real-world treatment patterns and standard of care treatment effectiveness and utilization outcomes in adult primary ITP patients indicated for second-line treatment with any prior corticosteroid treatment in real-world treatment settings in the United States (US) identified in an electronic health record (EHR) and claims database.
Adult patients diagnosed with primary ITP from a US medical claim and EHR data source during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary ITP patients with prior corticosteroid treatment being treated with second-line treatment.
Number and Percentage of Patients With Prescribed Second-line Treatments of Interest
Second-line treatments of interest, either as monotherapy or in a combination therapy, included: * Thrombopoietin Receptor Agonists (TPO-RAs): romiplostim, eltrombopag, avatrombopag. * Clusters of differentiation 20 (CD20) inhibitors: rituximab * Other therapies: fostamatinib * Immunosuppressants: azathioprine, mycophenolate mofetil * Splenectomy
Time frame: Up to approximately 8 years
Duration of Patient Follow-up
Time frame: Up to approximately 8 years
Time to Treatment Discontinuation (TTD)
Time frame: Up to approximately 8 years
Time to Next Treatment (TTNT)
Time frame: Up to approximately 8 years
Time to Next Treatment or Initiation of Rescue Treatment
Time frame: Up to approximately 8 years
Number and Percentage of Patients Who Discontinued Treatment Within 1, 3, and 6 Months of Second-line Treatment Initiation
Time frame: 1, 3, and 6 months
Number and Percentage of Patients by First Type of Activity Observed Following Treatment Discontinuation
Activities included: * Switch to new treatment * Restart the same second-line treatment * Have rescue treatment without second-line treatment * First-line treatment without second-line treatment * Enter a treatment-free interval * End of EHR/claims disenrollment * Death
Time frame: 1, 3, and 6 months
Number of Patients Who Entered a Treatment-free Interval
Treatment free interval was defined as at least 6 months with no second-line treatment or rescue treatment.
Time frame: Up to approximately 8 years
Duration of Treatment-free Interval
Treatment free interval was defined as at least 6 months with no second-line treatment or rescue treatment.
Time frame: Up to approximately 8 years
Number and Percentage of Combination Second-line Treatment Treated Patients Who Underwent Reductions
Reduction was defined as a discontinuation of at least one therapeutic agent with maintenance of at least one therapeutic agent.
Time frame: Up to approximately 8 years
Number and Percentage of Patients Who Used Add-on, Rescue, or Supportive Treatment During Second-line Treatment
An add-on was the inclusion of a new, additional second-line treatment ≥28 days after initiation of the initial second-line treatment.
Time frame: Up to approximately 8 years
Time to Initiation of Add-on or Rescue Treatment During Second-line Treatment
Time frame: Up to approximately 8 years
Time to Initiation of Supportive Treatment During Second-line Treatment
Time frame: Up to approximately 8 years
Platelet Counts
Time frame: 1, 3, and 6 months
Number and Percentage of Patients Who Achieved Pre-defined Platelet Counts Within 3 Months of Treatment Initiation
Measured among patients with at least one platelet count within 3 months of treatment initiation. Pre-defined platelet counts were categorized as follows: * ≥30 × 10\^9/L, * ≥ 50 × 10\^9/L, and * ≥100 × 10\^9/L
Time frame: 3 months
Number and Percentage of Patients With no Initial Response to Second-line Treatment
Measured among patients with at least one platelet count within 3 months of treatment initiation. No initial response was defined as platelet counts \<30 × 10\^9/L within 3 months of treatment initiation.
Time frame: 3 months
Number and Percentage of Patients Who Achieved Pre-defined Response Levels Within 6 Months of Treatment Initiation
Measured among patients with at least one platelet count within 6 months of treatment initiation. Response levels were categorized as follows: * response (≥ 50 × 10\^9/L), and * complete response (≥100 × 10\^9/L)
Time frame: 6 months
Among Patients With At Least Two Platelet Counts From 3 to 6 Months, Number and Percentage of Patients Who Reached Real-world Durable Response
Real-world durable response was defined as ≥75% of platelet counts ≥50 × 10\^9/L with a minimum of 2 platelet measurements and without other therapies.
Time frame: From 3 to 6 months
Among Patients With At Least Two Platelet Counts From 6 to 12 months, Number and Percentage of Patients Who Reached Real-world Durable Response
Real-world durable response was defined as ≥75% of platelet counts ≥50 × 10\^9/L with a minimum of 2 platelet measurements and without other therapies.
Time frame: From 6 to 12 months
Number and Percentage of Patients With Emergency Department (ED) or Inpatient (IP) Thrombotic Events Within 12 Months After Second-line Treatment Initiation
Thrombotic events may have included pulmonary embolism, deep vein thrombosis, cerebral venous thrombosis, transient ischemic attack.
Time frame: 12 months
Number of Thrombotic Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years
Time frame: 12 months
Number and Percentage of Patients With Infection Events Within 12 Months After Second-line Treatment Initiation
Time frame: 12 months
Number of Infection Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years
Time frame: 12 months
Number and Percentage of Patients With Bleeding Events Within 12 Months After Second-line Treatment Initiation
Time frame: 12 months
Number of Bleeding Events Within 12 Months After Second-line Treatment Initiation, per 1000 Person-years
Time frame: 12 months
Overall Survival (OS)
Time frame: 12 months
Number and Percentage of Patients With At Least One Healthcare Visit After Second-line Treatment Initiation
Healthcare visits included outpatient visits, IP admissions, intensive care unit (ICU) admissions, and ED visits.
Time frame: 12 months
Number of Healthcare Visits After Second-line Treatment Initiation, per Patient per Year (PPPY)
Healthcare visits included outpatient visits, IP admissions, ICU admissions, and ED visits.
Time frame: 12 months
Number of Oral Corticosteroid Medication Fills Within 12 Months After Second-line Treatment Initiation, PPPY
Time frame: 12 months
Number of Days With Active Oral Corticosteroid Prescriptions Within 12 Months After Second-line Treatment Initiation, PPPY
Time frame: 12 months
Duration of IP and ICU Admissions Among Patients Who Were Hospitalized After Second-line Treatment Initiation
Time frame: 12 months
Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Failed Treatment
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months. Treatment failure was defined as platelet count \<30 × 10\^9/L.
Time frame: Up to approximately 8 years
Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Received Rescue Treatment
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to approximately 8 years
Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Initiated a New Second-line Treatment or Added Oral Corticosteroids
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to approximately 8 years
Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Died
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to approximately 8 years
Number and Percentage of Patient Responders From Date of First Response Through the End of Follow-up, Who Reached the End of the Study Period
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to approximately 8 years
Among Patient Responders, Time From Second-line Treatment Initiation to Response
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to 6 months
Among Patient Responders, Duration of Platelet Response
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months.
Time frame: Up to approximately 8 years
Number and Percentage of Patient Responders With Treatment-free Response
Patient responders were defined as patients who reach a response level of ≥ 50 × 10\^9/L within 6 months. Treatment-free response was defined as platelet count ≥30 × 10\^9/L at 3 months after discontinuing second-line treatment.
Time frame: Up to 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Nov 2025, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombocytopenic, Idiopathic →